08.03.19: Not intended for U.S. and UK Media

Bayer submits European marketing authorization application for darolutamideThird submission for darolutamide in two weeks underscores Bayer's commitment to fill an unmet need for men with nmCRPC worldwide / Regulatory submission based on positive data from Phase III study ARAMISmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news